<p>Biocon Biologics, a subsidiary of Bengaluru-based pharmaceutical company Biocon, said that the interchangeable insulin Glargine (Semglee) has been listed as a preferred glargine brand on the National Preferred Formulary (NPF) by Express Scripts, a leading pharmacy benefit management organisation in the US.</p>.<p>Semglee has been jointly developed by Biocon Biologics and Viatris.</p>.<p>“Viatris will soon commercialise two versions of our landmark Insulin Glargine injection, the first-ever interchangeable biosimilar approved by the US Food and Drug Administration (FDA): Semglee (insulin glargine-yfgn) injection, a branded interchangeable product, and Insulin Glargine (insulin glargine-yfgn) injection, an authorised interchangeable biosimilar,” Biocon Biologics said in its statement.</p>.<p>Both products will be available in pen and vial presentations and are interchangeable for the reference brand, Lantus.</p>.<p><strong>Watch latest videos by DH here:</strong></p>
<p>Biocon Biologics, a subsidiary of Bengaluru-based pharmaceutical company Biocon, said that the interchangeable insulin Glargine (Semglee) has been listed as a preferred glargine brand on the National Preferred Formulary (NPF) by Express Scripts, a leading pharmacy benefit management organisation in the US.</p>.<p>Semglee has been jointly developed by Biocon Biologics and Viatris.</p>.<p>“Viatris will soon commercialise two versions of our landmark Insulin Glargine injection, the first-ever interchangeable biosimilar approved by the US Food and Drug Administration (FDA): Semglee (insulin glargine-yfgn) injection, a branded interchangeable product, and Insulin Glargine (insulin glargine-yfgn) injection, an authorised interchangeable biosimilar,” Biocon Biologics said in its statement.</p>.<p>Both products will be available in pen and vial presentations and are interchangeable for the reference brand, Lantus.</p>.<p><strong>Watch latest videos by DH here:</strong></p>
